Description: Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Home Page: www.orion.fi
Orionintie 1A
Espoo,
02200
Finland
Phone:
358 10 4261
Officers
| Name | Title |
|---|---|
| Mr. Timo Lappalainen | Advisor |
| Dr. Liisa Hurme | Pres, CEO & Chairman of Exec. Management Board |
| Mr. Jari Karlson M.Sc., M.Sc. (Econ.) | CFO, Sr. VP of Animal Health & Member of the Exec. Management Board |
| Mr. Olli Huotari Ll.M. | Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board |
| Ms. Virve Laitinen M.Sc. (Tech.), MBA | Sr. VP of Specialty Products & Member of Exec. Management Board |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP for R&D and Member of Exec. Management Board |
| Mr. Juhani Kankaanpaa | Sr. VP of Global Operations & Member of Exec. Management Board |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer |
| Ms. Terhi Ormio | VP of Communications |
Exchange: HE
Country: FI
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 26.1097 |
|---|---|
| Trailing PE: | 22.0884 |
| Price-to-Book MRQ: | 7.277 |
| Price-to-Sales TTM: | 5.2909 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3527 |